Douglas Hanahan

186.6k total citations · 33 hit papers
230 papers, 137.2k citations indexed

About

Douglas Hanahan is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Douglas Hanahan has authored 230 papers receiving a total of 137.2k indexed citations (citations by other indexed papers that have themselves been cited), including 118 papers in Molecular Biology, 88 papers in Oncology and 58 papers in Genetics. Recurrent topics in Douglas Hanahan's work include Pancreatic function and diabetes (49 papers), Angiogenesis and VEGF in Cancer (31 papers) and Virus-based gene therapy research (29 papers). Douglas Hanahan is often cited by papers focused on Pancreatic function and diabetes (49 papers), Angiogenesis and VEGF in Cancer (31 papers) and Virus-based gene therapy research (29 papers). Douglas Hanahan collaborates with scholars based in United States, Switzerland and United Kingdom. Douglas Hanahan's co-authors include Robert A. Weinberg, Judah Folkman, Gabriele Bergers, Lisa M. Coussens, Zena Werb, Oriol Casanovas, Matthew Meselson, Nicole Meyer-Morse, Peter Olson and J Folkman and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Douglas Hanahan

226 papers receiving 134.0k citations

Hit Papers

Hallmarks of Cancer: The Ne... 1980 2026 1995 2010 2011 2000 1983 1996 2012 10.0k 20.0k 30.0k 40.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Hallmarks of Cancer: The Next Generation
    2011 48.4k citations Douglas Hanahan, Robert A. Weinberg Cell profile →
  2. The Hallmarks of Cancer
    2000 21.2k citations Douglas Hanahan, Robert A. Weinberg Cell profile →
  3. Studies on transformation of Escherichia coli with plasmids
    1983 9.8k citations Douglas Hanahan profile →
  4. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis
    1996 5.6k citations Douglas Hanahan, Judah Folkman Cell profile →
  5. Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
    2012 3.4k citations Douglas Hanahan, Lisa M. Coussens Cancer Cell profile →
  6. Modes of resistance to anti-angiogenic therapy
    2008 2.3k citations Gabriele Bergers, Douglas Hanahan profile →
  7. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
    2000 2.2k citations Gabriele Bergers, Douglas Hanahan et al. profile →
  8. Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
    2009 1.9k citations Elizabeth Allen, Gabriele Bergers et al. Cancer Cell profile →
  9. Induction of angiogenesis during the transition from hyperplasia to neoplasia
    1989 1.6k citations Douglas Hanahan et al. profile →
  10. MMP-9/Gelatinase B Is a Key Regulator of Growth Plate Angiogenesis and Apoptosis of Hypertrophic Chondrocytes
    1998 1.5k citations Gabriele Bergers, Douglas Hanahan et al. Cell profile →
  11. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
    2005 1.3k citations Oriol Casanovas, Daniel J. Hicklin et al. Cancer Cell profile →
  12. Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-κB-Dependent Manner
    2010 1.2k citations Morgan Truitt, Peter Olson et al. Cancer Cell profile →
  13. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
    2011 1.2k citations Anguraj Sadanandam, Peter Olson et al. profile →
  14. Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes
    1985 1.1k citations Douglas Hanahan profile →
  15. MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis
    2000 1.1k citations Lisa M. Coussens, Douglas Hanahan et al. Cell profile →
  16. Plasmid screening at high colony density
    1980 1.0k citations Douglas Hanahan et al. profile →
  17. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
    2003 1.0k citations Gabriele Bergers, Nicole Meyer-Morse et al. profile →
  18. Differential plasmid rescue from transgenic mouse DNAs into Escherichia coli methylation-restriction mutants.
    1990 975 citations Douglas Hanahan et al. Proceedings of the National Academy of Sciences profile →
  19. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
    2003 971 citations Gabriele Bergers, Nicole Meyer-Morse et al. profile →
  20. Tissue-Penetrating Delivery of Compounds and Nanoparticles into Tumors
    2009 925 citations Douglas Hanahan, Erkki Ruoslahti et al. Cancer Cell profile →
  21. Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice
    1999 811 citations Gabriele Bergers, Judah Folkman et al. profile →
  22. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis
    1999 736 citations Lisa M. Coussens, Gabriele Bergers et al. profile →
  23. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis
    2006 728 citations Christopher Chiu, Douglas Hanahan et al. Proceedings of the National Academy of Sciences profile →
  24. A colorectal cancer classification system that associates cellular phenotype and responses to therapy
    2013 721 citations Anguraj Sadanandam, Costas A. Lyssiotis et al. profile →
  25. Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
    2017 589 citations Elizabeth Allen, Douglas Hanahan et al. Science Translational Medicine profile →
  26. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer
    2006 506 citations Peter Olson, Douglas Hanahan et al. profile →
  27. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis
    2004 504 citations Johanna A. Joyce, Nicole Meyer-Morse et al. Cancer Cell profile →
  28. An amino-bisphosphonate targets MMP-9–expressing macrophages and angiogenesis to impair cervical carcinogenesis
    2004 500 citations Enrico Giraudo, Douglas Hanahan et al. profile →
  29. Beta-cell lines derived from transgenic mice expressing a hybrid insulin gene-oncogene.
    1988 444 citations Douglas Hanahan et al. Proceedings of the National Academy of Sciences profile →
  30. Genetic and physical linkage of exogenous sequences in transformed cells
    1980 418 citations Manuel Perucho, Douglas Hanahan et al. Cell profile →
  31. Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer
    2015 381 citations Andrew J. Gunderson, Megan M. Kaneda et al. Cancer Discovery profile →
  32. Synaptic proximity enables NMDAR signalling to promote brain metastasis
    2019 352 citations Iacovos P. Michael, Sadegh Saghafinia et al. profile →
  33. Cancer hallmarks intersect with neuroscience in the tumor microenvironment
    2023 151 citations Douglas Hanahan et al. Cancer Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Douglas Hanahan United States 109 79.7k 43.8k 36.5k 19.2k 13.4k 230 137.2k
Zena Werb United States 151 45.6k 0.6× 35.3k 0.8× 33.6k 0.9× 18.5k 1.0× 7.9k 0.6× 416 110.4k
Kenneth W. Kinzler United States 163 79.7k 1.0× 49.2k 1.1× 37.4k 1.0× 8.0k 0.4× 14.8k 1.1× 381 131.7k
Joan Massagué United States 184 95.5k 1.2× 47.2k 1.1× 22.6k 0.6× 12.3k 0.6× 9.3k 0.7× 362 137.5k
Adrian L. Harris United Kingdom 164 64.9k 0.8× 34.9k 0.8× 45.7k 1.3× 10.5k 0.5× 8.0k 0.6× 1.2k 109.9k
Lewis C. Cantley United States 183 104.9k 1.3× 27.4k 0.6× 29.7k 0.8× 16.8k 0.9× 7.3k 0.5× 710 150.4k
Craig B. Thompson United States 182 91.8k 1.2× 25.3k 0.6× 44.6k 1.2× 36.7k 1.9× 7.1k 0.5× 515 151.3k
Hans Clevers Netherlands 190 98.0k 1.2× 53.3k 1.2× 18.5k 0.5× 15.0k 0.8× 24.3k 1.8× 728 159.5k
Robert A. Weinberg United States 176 135.1k 1.7× 95.3k 2.2× 56.3k 1.5× 25.8k 1.3× 18.3k 1.4× 382 223.8k
Bert Vogelstein United States 204 134.2k 1.7× 91.6k 2.1× 56.8k 1.6× 15.1k 0.8× 28.7k 2.1× 553 229.5k
Gregg L. Semenza United States 164 64.3k 0.8× 15.5k 0.4× 69.1k 1.9× 9.6k 0.5× 15.1k 1.1× 423 116.8k

Countries citing papers authored by Douglas Hanahan

Since Specialization
Citations

This map shows the geographic impact of Douglas Hanahan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Hanahan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Hanahan more than expected).

Fields of papers citing papers by Douglas Hanahan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas Hanahan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Hanahan. The network helps show where Douglas Hanahan may publish in the future.

Co-authorship network of co-authors of Douglas Hanahan

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas Hanahan. A scholar is included among the top collaborators of Douglas Hanahan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas Hanahan. Douglas Hanahan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Marcone, Rachel, Elin Jaensson Gyllenbäck, David Liberg, et al.. (2025). HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine. Cancer Discovery. 15(7). 1458–1483.
2.
Saghafinia, Sadegh, Krisztián Homicskó, Annunziata Di Domenico, et al.. (2021). Cancer Cells Retrace a Stepwise Differentiation Program during Malignant Progression. Cancer Discovery. 11(10). 2638–2657. 29 indexed citations
3.
Wullschleger, Stephan, Mélanie Tichet, Dhaarini Murugan, et al.. (2019). Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV+ Cancers. Cancer Immunology Research. 8(1). 131–145. 28 indexed citations
4.
Tichet, Mélanie, Sonia Domingos‐Pereira, Sylvie Hauert, et al.. (2018). Nanoparticle Conjugation of Human Papillomavirus 16 E7-long Peptides Enhances Therapeutic Vaccine Efficacy against Solid Tumors in Mice. Cancer Immunology Research. 6(11). 1301–1313. 30 indexed citations
5.
Fankhauser, Manuel, Maria A.S. Broggi, Lambert Potin, et al.. (2017). Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma. Science Translational Medicine. 9(407). 190 indexed citations
6.
Gunderson, Andrew J., Megan M. Kaneda, Takahiro Tsujikawa, et al.. (2015). Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer. Cancer Discovery. 6(3). 270–285. 381 indexed citations breakdown →
7.
Sadanandam, Anguraj, Stephan Wullschleger, Costas A. Lyssiotis, et al.. (2015). A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics. Cancer Discovery. 5(12). 1296–1313. 139 indexed citations
8.
Godinat, Aurélien, Hyo Min Park, Stephen C. Miller, et al.. (2013). A Biocompatible in Vivo Ligation Reaction and Its Application for Noninvasive Bioluminescent Imaging of Protease Activity in Living Mice. ACS Chemical Biology. 8(5). 987–999. 52 indexed citations
9.
Allen, Elizabeth, Ian Walters, & Douglas Hanahan. (2011). Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition. Clinical Cancer Research. 17(16). 5299–5310. 114 indexed citations
10.
Hanahan, Douglas & Robert A. Weinberg. (2011). Hallmarks of Cancer: The Next Generation. Cell. 144(5). 646–674. 48448 indexed citations breakdown →
11.
Chun, Matthew G. H., Jian‐Hua Mao, Christopher Chiu, Allan Balmain, & Douglas Hanahan. (2010). Polymorphic genetic control of tumor invasion in a mouse model of pancreatic neuroendocrine carcinogenesis. Proceedings of the National Academy of Sciences. 107(40). 17268–17273. 18 indexed citations
12.
Zhang, Lianglin, Enrico Giraudo, Jason A. Hoffman, Douglas Hanahan, & Erkki Ruoslahti. (2006). Lymphatic Zip Codes in Premalignant Lesions and Tumors. Cancer Research. 66(11). 5696–5706. 60 indexed citations
13.
Joyce, Johanna A., Craig Freeman, Nicole Meyer-Morse, Christopher R. Parish, & Douglas Hanahan. (2005). A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene. 24(25). 4037–4051. 135 indexed citations
14.
Casanovas, Oriol, Daniel J. Hicklin, Gabriele Bergers, & Douglas Hanahan. (2005). Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 8(4). 299–309. 1291 indexed citations breakdown →
15.
Hager, Jeffrey H., John Hodgson, Jane Fridlyand, et al.. (2004). Oncogene Expression and Genetic Background Influence the Frequency of DNA Copy Number Abnormalities in Mouse Pancreatic Islet Cell Carcinomas. Cancer Research. 64(7). 2406–2410. 22 indexed citations
16.
Astrof, Sophie, Denise Crowley, Elizabeth George, et al.. (2004). Direct Test of Potential Roles of EIIIA and EIIIB Alternatively Spliced Segments of Fibronectin in Physiological and Tumor Angiogenesis. Molecular and Cellular Biology. 24(19). 8662–8670. 86 indexed citations
17.
Gasparini, Giulio, Douglas Hanahan, Gerhard Christofori, et al.. (1996). Basic and clinical research on angiogenesis. Vascular. 2401. 2412–2412. 1 indexed citations
18.
Hanahan, Douglas & Judah Folkman. (1996). Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis. Cell. 86(3). 353–364. 5590 indexed citations breakdown →
19.
Hanahan, Douglas, Hugh O. McDevitt, & George F. Cahill. (1989). Perspectives on the molecular biology and immunology of the pancreatic β cell. 1 indexed citations
20.
Wigler, Michael, Manuel Perucho, Leah Lipsich, et al.. (1980). DNA Mediated Gene Transfer: Theory and Application. Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zena Werb Breakdown of academic impact, for papers by Kenneth W. Kinzler Breakdown of academic impact, for papers by Joan Massagué Breakdown of academic impact, for papers by Adrian L. Harris Breakdown of academic impact, for papers by Lewis C. Cantley Breakdown of academic impact, for papers by Craig B. Thompson Breakdown of academic impact, for papers by Hans Clevers Breakdown of academic impact, for papers by Robert A. Weinberg Breakdown of academic impact, for papers by Bert Vogelstein Breakdown of academic impact, for papers by Gregg L. Semenza
Rankless by CCL
2026